

Health Care Provider Bulletin

LifeLabs Service Updates 02/04/2026

Alzheimer's A β 42/40 with p-tau217 Testing is Available at LifeLabs

Dear valued Health Care Provider,

LifeLabs is proud to support you by offering one of the industry's most comprehensive portfolios of blood-based biomarker tests for assessing dementia and Alzheimer's disease. Our portfolio includes the A β 42/40 ratio and p-tau217 Evaluation panel, the standalone p-tau217, and the A β 42/40 ratio.

Importantly, the LifeLabs A β 42/40 and p-tau217 Evaluation panel is a CLIA-cleared laboratory-developed test and is distinct from the Fujirebio Lumipulse p-tau217/A β 42 assay, as such, our test is not affected by the current quality hold on the Fujirebio assay. The LifeLabs' A β 42/40 ratio and p-tau217 Evaluation panel provides reliable risk stratification by estimating the likelihood of amyloid PET positivity (categorized as low, indeterminate, or high).¹ Performance characteristics include:

- Sensitivity: 91%
- Specificity: 91%
- Positive predictive value: 87% (at an estimated disease prevalence of ~46%)
- Negative predictive value: 91% (at an estimated disease prevalence of ~46%)

What This Means for You

Testing for the A β 42/40 ratio with p-tau217, using the Evaluation panel, remains available through LifeLabs. Test requests can be submitted using the [Alzheimer's custom requisition form](#) or a BC standard laboratory requisition form by writing test names in the 'Other Tests' section.

When used for patients with mild cognitive impairment (MCI), this panel meets or exceeds the Alzheimer's CEO Initiative (CEOi) performance standards for confirmatory blood-based biomarkers.²

Thank you for your continued trust in our laboratory services. We remain committed to supporting your Alzheimer's testing needs with high-quality, evidence-based insights and care.

If you have any questions, please contact the LifeLabs Customer Care Centre at 1-800-431-7206.

For more information on our full Alzheimer's disease test offering, please click [here](#).

Sincerely,

LifeLabs

1. Weber, Darren M et al. "Development and Clinical Validation of Blood-Based Multibiomarker Models for the Evaluation of Brain Amyloid Pathology." *Neurology. Clinical practice* vol. 15,6 (2025): e200546. doi:10.1212/CPJ.0000000000200546
2. <https://alzdiagnostichub.org/bbm-performance-standards/>